Biologic Therapies in Asthma: Are We Overlooking Patients with Normal Lung Function? - Amsterdam 2025

Biologics for asthma: navigating specific/complex patient populations

Chair(s): Matteo Bonini, Clairelyne Dupin

Session type: Poster session

Biologic Therapies in Asthma: Are We Overlooking Patients with Normal Lung Function?

Elena Rodríguez Lobato

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

The effect of biological treatment on symptoms in patients with NSAID-Exacerbated Respiratory Disease

Kurtulus Aksu

Poster

Abstract

Biologics for Asthma in genetic lung diseases *Ashkenazi M¹ ², *Boaron Azaria S², Heching M3 2, Levin H2 4, Gur M 6 5, Shteinberg M4 6, Efrati O¹ ²

Sivan Boaron Azaria

Poster

Abstract

Late Breaking Abstract - Efficacy of a monoclonal antibody against IL-25 in human allergic asthma: an open-label, single-arm, phase Ic study

Wen Hua

Poster

Abstract

DOES AGE AFFECT EFFECTIVENESS AND SAFETY OF BIOLOGICAL DRUGS IN ELDERLY SEVERE ASTHMATICS?

Lorena Gentile

Poster

Abstract

Efficacy of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps and comorbid NSAID-exacerbated respiratory disease (WAYPOINT)

Brian J. Lipworth

Poster

Abstract

Patterns of oral corticosteroid and biologic use in people with uncontrolled difficult-to-treat asthma in New Zealand

Amy Hai Yan Chan

Poster

Abstract

Predicting Biologic Therapy Sparing in Severe Asthma and Small Airway Disease: One-Year Outcomes of Single Inhaler Triple Therapy

Vitaliano Nicola Quaranta

Poster

Abstract

Severe asthma with and without long-term oral corticosteroids (OCS): A comparison of disease severity and baseline characteristics

Roland Buhl

Poster

Abstract

Assessment the use of oral corticosteroid and biologics in severe asthma patients living in Switzerland: A national pharmacy cohort

Pierre-olivier Bridevaux

Poster

Abstract

COMPARATIVE STUDY OF CLINICAL FUNCTIONAL CHARACTERISTICS AND TREATMENT EFFECTIVENESS BETWEEN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA (SUA) AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) TREATED WITH MEPOLIZUMAB

Antonio León Lloreda

Poster

Abstract

Real-world efficacy and cost-effectiveness of omalizumab in asthma with chronic rhinosinusitis and nasal polyps (CRSwNP)

Xiaohan Xu

Poster

Abstract

Mepolizumab-induced changes in patients with nasal polyps and comorbid asthma: preliminary results on airway microbiome and transcriptome

Heleni Loutrari

Poster

Abstract

Biologic Therapies in Asthma: Are We Overlooking Patients with Normal Lung Function?

Elena Rodríguez Lobato

Poster

Abstract

Hereditary ?-tryptasemia in severe asthma is linked to impaired lung function, lower type 2 biomarkers, and poor omalizumab response

Peter Kopac

Poster

Abstract

Depression and anxiety in severe asthma patients qualified to biological therapy

Malgorzata Farnik

Poster

Abstract

Impact of psychological stress on disease control of subjects treated by biologicals for severe asthma

Anna Breslavsky

Abstract

Unmasking of Eosinophilic Granulomatosis With Polyangiitis by the initiation of Dupilumab in severe asthma : A Case Series.

Albatol Rashed

Poster

Abstract

Birth outcomes in severe asthma patients on biologic therapy: a retrospective analysis

Alice Rose Jefferson

Poster

Abstract

Benralizumab efficacy in a real-life cohort of severe asthma and eosinophilic granulomatosis with polyangiitis patients

Alvaro Martinez Mesa

Poster

Abstract

Late Breaking Abstract - Effect of anti-IL5 treatment on upper airway basement membrane thickness in patients with CRSwNP and mild asthma preliminary results

Nikoleta Bizymi

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}